Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Bone and Soft Tissue Sarcoma (BIOVAS)
NCT04072042Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2019
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in bone sarcoma, soft tissue sarcoma (STS), sponsored by Ruijin Hospital. Started Oct 2019; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04072042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072042.